Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | FGFR2 E768* |
| Therapy | Fexagratinib |
| Indication/Tumor Type | breast cancer |
| Response Type | predicted - sensitive |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| FGFR2 E768* | breast cancer | predicted - sensitive | Fexagratinib | Preclinical | Actionable | In a preclinical study, Fexagratinib (AZD4547) inhibited FGFR2 signaling and growth in mouse mammary epithelial cells expressing FGFR2 E673* (corresponding to E768* in human) in culture and inhibited tumor growth in an orthotopic model (PMID: 35948633). | 35948633 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (35948633) | Truncated FGFR2 is a clinically actionable oncogene in multiple cancers. | Full reference... |